Charles River Laboratories International, Inc. (CRL) Stock Report
Publication Date: September 22, 2024
Company Overview
Charles River Laboratories International, Inc. (CRL), based in Wilmington, Massachusetts, is a leading entity in the healthcare sector, specifically the Diagnostics & Research industry. Founded in 1947, CRL provides an array of services crucial for drug discovery, non-clinical development, and safety testing on a global scale, including key markets in the United States, Europe, Canada, and Asia Pacific. The firm operates across three principal segments:
- Research Models and Services: Specializing in purpose-bred rodents for research;
- Discovery and Safety Assessment: Supporting the identification and validation of drug candidates;
- Manufacturing Solutions: Focusing on quality control testing for pharmaceuticals and consumer products.
Notably, CRL has reported robust performance with a total revenue of approximately $4.08 billion. Analysts’ optimistic outlook recommends a “buy,” emphasizing the potential for significant growth.
Stock Performance Analysis
As of now, Charles River Laboratories’ stock is priced at $205.79, with the analysts setting a high target price of $259.21, suggesting a prospective upside of about 26%. The average target price is positioned at $224.59, reflecting a more conservative estimate that still represents a potential gain of roughly 9%. With 51,630,700 shares outstanding and a short interest accounting for about 3.66% of the float, the stock is experiencing relatively low bearish sentiment, indicating stability.
The financial landscape suggests a price volatility, evidenced by a fifty-two-week high of $275.00 and a low of $161.65. The current price indicates that CRL is trading closer to the lower end of this range, hinting at potential undervaluation and an opportunity for discerning investors.
Analyst Sentiment
Further solidifying the positive outlook is a recommendation mean of 2.5 from 14 analysts, denoting a generally favorable perspective on CRL’s valuation. The broad target price range from $191.00 to $259.21 further illustrates the potential variability in the stock’s future performance. While specific figures for EBITDA are unavailable, the strong revenue indicates solid sales performance. Overall, the market sentiment, reinforced by analysts’ consensus, presents a compelling investment case for those considering Charles River Laboratories International, Inc.
| Metric | Value |
|---|---|
| Market Cap | $10.6b |
| Total Debt | $2.8b |
| Total Cash | $179.2m |
| Shares Outstanding | 51.6m |
| Float Shares | 51.0m |
Disclaimer:
The information provided in this monthly report is for informational purposes only and should not be construed as financial, investment, or trading advice. AltStation.io does not guarantee the accuracy, completeness, or timeliness of the data and analyses presented. The content is based on publicly available information, and while we strive to ensure its accuracy, errors and omissions may occur.
Investing in stocks, cryptocurrencies, and other financial instruments involves significant risk, including the potential loss of principal. Past performance is not indicative of future results. Readers should conduct their own research and consult with a qualified financial advisor before making any investment decisions. AltStation.io and its affiliates are not responsible for any losses incurred as a result of using this report.
By using this report, you acknowledge that you understand and accept these terms.